Logo image of AIM

AIM IMMUNOTECH INC (AIM) Stock Price, Quote, News and Overview

NYSEARCA:AIM - NYSE Arca - US00901B1052 - Common Stock - Currency: USD

0.1383  0 (-3.15%)

After market: 0.135 0 (-2.39%)

AIM Quote, Performance and Key Statistics

AIM IMMUNOTECH INC

NYSEARCA:AIM (2/21/2025, 8:04:00 PM)

After market: 0.135 0 (-2.39%)

0.1383

0 (-3.15%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High0.62
52 Week Low0.12
Market Cap8.82M
Shares63.78M
Float57.69M
Yearly Dividend0
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-31 2025-03-31/amc
IPO07-12 1996-07-12


AIM short term performance overview.The bars show the price performance of AIM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

AIM long term performance overview.The bars show the price performance of AIM in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of AIM is 0.1383 USD. In the past month the price decreased by -38.51%. In the past year, price decreased by -66.88%.

AIM IMMUNOTECH INC / AIM Daily stock chart

AIM Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About AIM

Company Profile

AIM logo image AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 26 full-time employees. The company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Company Info

AIM IMMUNOTECH INC

2117 Sw Highway 484

Ocala FLORIDA 34473 US

CEO: Thomas K. Equels

Employees: 27

Company Website: https://aimimmuno.com/

Investor Relations: http://ir.hemispherx.net/

Phone: 13524487797

AIM IMMUNOTECH INC / AIM FAQ

What is the stock price of AIM IMMUNOTECH INC today?

The current stock price of AIM is 0.1383 USD. The price decreased by -3.15% in the last trading session.


What is the ticker symbol for AIM IMMUNOTECH INC stock?

The exchange symbol of AIM IMMUNOTECH INC is AIM and it is listed on the NYSE Arca exchange.


On which exchange is AIM stock listed?

AIM stock is listed on the NYSE Arca exchange.


What is the price forecast or stock price prediction for AIM IMMUNOTECH INC stock?

6 analysts have analysed AIM and the average price target is 2.81 USD. This implies a price increase of 1928.2% is expected in the next year compared to the current price of 0.1383. Check the AIM IMMUNOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AIM IMMUNOTECH INC worth?

AIM IMMUNOTECH INC (AIM) has a market capitalization of 8.82M USD. This makes AIM a Nano Cap stock.


How many employees does AIM IMMUNOTECH INC have?

AIM IMMUNOTECH INC (AIM) currently has 27 employees.


What are the support and resistance levels for AIM IMMUNOTECH INC (AIM) stock?

AIM IMMUNOTECH INC (AIM) has a resistance level at 0.2. Check the full technical report for a detailed analysis of AIM support and resistance levels.


Is AIM IMMUNOTECH INC (AIM) expected to grow?

The Revenue of AIM IMMUNOTECH INC (AIM) is expected to decline by -7.64% in the next year. Check the estimates tab for more information on the AIM EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AIM IMMUNOTECH INC (AIM) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AIM IMMUNOTECH INC (AIM) stock pay dividends?

AIM does not pay a dividend.


When does AIM IMMUNOTECH INC (AIM) report earnings?

AIM IMMUNOTECH INC (AIM) will report earnings on 2025-03-31, after the market close.


What is the Price/Earnings (PE) ratio of AIM IMMUNOTECH INC (AIM)?

AIM IMMUNOTECH INC (AIM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.48).


What is the Short Interest ratio of AIM IMMUNOTECH INC (AIM) stock?

The outstanding short interest for AIM IMMUNOTECH INC (AIM) is 1.59% of its float. Check the ownership tab for more information on the AIM short interest.


AIM Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

AIM Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to AIM. Both the profitability and financial health of AIM have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AIM Financial Highlights

Over the last trailing twelve months AIM reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS decreased by -12.56% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -176.1%
ROE -821.74%
Debt/Equity 0.05
Chartmill High Growth Momentum
EPS Q2Q%60%
Sales Q2Q%-23.91%
EPS 1Y (TTM)-12.56%
Revenue 1Y (TTM)-1.55%

AIM Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to AIM. The Buy consensus is the average rating of analysts ratings from 6 analysts.

For the next year, analysts expect an EPS growth of 41.93% and a revenue growth -7.64% for AIM


Ownership
Inst Owners7.29%
Ins Owners9.54%
Short Float %1.59%
Short Ratio0.92
Analysts
Analysts80
Price Target2.81 (1931.81%)
EPS Next Y41.93%
Revenue Next Year-7.64%